Centyrin ligands for extrahepatic delivery of siRNA
Donna Klein(Springhouse), Vadim Dudkin(United States Military Academy), Kathleen Haskell(Upsher-Smith Laboratories (United Kingdom)), Mei‐Zhen Wu(Queen Mary Hospital), Tricia Lin(Janssen (United States)), Shalom D. Goldberg(Janssen (United States)), Richard Dambra(Janssen (United States)), Vasant Jadhav(Alnylam Pharmaceuticals (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Elise Kuhar(Janssen (United States)), Karyn T. O’Neil(Janssen (United States)), Rubina Parmar(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Christopher S. Theile(Alnylam Pharmaceuticals (United States)), Mark C. Richter(GlaxoSmithKline (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Jeannine Mendrola Zarazowski(Janssen (United States))
Cited by 48
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k